New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositions
CA 2454734 A1 · Owner: Abastado, Jean-Pierre · Inventors: Kaiser, Andrew; Nardin, Alessandra; Abastado, Jean-Pierre
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to dendritic cells irreversibly triggered to maturation which are CD14 positive, which express MHC class I with a median fluorescence intensity less than about 1500 and CD86 with a median fluorescence intensity less than about 500, as determined by immunofluorescence staining and flow cytometry analysis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 16, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 16, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 16, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.